Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Multicenter, Dose-Escalation and Dose Optimization Study of SYNC-T Therapy SV-102 for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06533644 is registered in ClinicalTrials.gov with Syncromune, Inc. as lead sponsor.

NCT NCT06533644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06533644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Multicenter, Dose-Escalation and Dose Optimization Study of SYNC-T Therapy SV-102 for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Lead sponsor
Syncromune, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
May 29, 2025
Completion date
April 14, 2028
Enrollment
91 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer